<!-- modules/module85.html -->
<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Dinoprostone - KMTC Pharmacology Notes</title>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Dinoprostone - KMTC Pharmacology Notes</title>
    <meta name="description" content="This module covers Dinoprostone, a synthetic prostaglandin E2 analog, detailing their uses and nursing considerations in obstetrics.">
</head>
<body>
    <article class="learning-module" data-module="85">
        <nav class="module-nav">
            <div class="nav-links">
              <a href="../index.html">Home</a>
              <a href="module84.html">Previous</a>
              <a href="module86.html">Next</a>
            </div>
            <div class="module-progress">
              <span>Module 85 of 89</span>
            </div>
          </nav>

        <header class="module-header">
            <h1>Dinoprostone</h1>
            <section class="module-objectives">
                <h2>üéØ Learning Objectives</h2>
                <ul>
                    <li>Describe Dinoprostone as a synthetic prostaglandin E2 (PGE2) analog and its obstetric uses.</li>
                    <li>Explain the mechanism of action of Dinoprostone in cervical ripening and labor induction.</li>
                    <li>Identify the indications and dosages for Dinoprostone administration.</li>
                    <li>Discuss the contraindications, adverse reactions, and precautions associated with Dinoprostone use.</li>
                    <li>Detail the nursing considerations for administering Dinoprostone, emphasizing monitoring uterine activity and fetal well-being.</li>
                </ul>
            </section>
        </header>

        <main class="module-content">
            <section class="content-section">
                <h2>üìö Dinoprostone: Prostaglandin E2 Analog</h2>
                <div class="content-block">
                    <p><strong>Dinoprostone</strong>, also known as prostaglandin E2 (PGE2), is a synthetic prostaglandin analog used primarily in obstetrics to ripen the cervix and induce labor. It mimics the action of naturally occurring prostaglandin E2, which plays a key role in cervical ripening and uterine contractions at the end of pregnancy. Key features of dinoprostone include:</p>
                    <ul>
                        <li>Class: Oxytocic, prostaglandin.</li>
                        <li>Pregnancy risk category C: Indicates potential risks during pregnancy, particularly when used near term, but benefits may outweigh risks in certain situations, such as labor induction.</li>
                        <li>Action: Dinoprostone initiates strong contractions of uterine smooth muscle by:
                            <ul>
                                <li>Stimulating Myometrium: Directly stimulating the myometrium (uterine muscle), leading to uterine contractions.</li>
                                <li>Promoting Cervical Ripening: Causing cervical softening, effacement (thinning), and dilation. This ripening effect is crucial for successful labor induction, making the cervix more favorable for dilation and passage of the fetus.</li>
                            </ul>
                        </li>
                    </ul>
                     <figure class="content-image">
                        <img src="../assets/images/KMTC_Pharmacology.jpg"
                             alt="Diagram illustrating Dinoprostone's action on the uterus, showing stimulation of uterine smooth muscle contractions and promotion of cervical ripening, effacement, and dilation."
                             width="600" height="300">
                        <figcaption>Dinoprostone: Action on Uterus</figcaption>
                    </figure>
                </div>
            </section>

            <section class="content-section">
                <h2>üìö Indications and dosages</h2>
                <div class="content-block">
                    <section class="content-section">
                        <h3>Indications and dosages</h3>
                        <div class="content-block">
                            <ol>
                                <li>Cervical ripening: To initiate cervical ripening at or near term when induction of labor is indicated.
                                    <ul>
                                        <li>Cervidil Vaginal Insert: A vaginal insert formulation containing 10 mg of dinoprostone, designed for slow release over 12 hours. Insert is placed in the posterior fornix of the vagina.</li>
                                        <li>Prepidil Endocervical Gel: An endocervical gel containing 0.5 mg dinoprostone. Administered via syringe into the cervical canal. If response is poor, may repeat dose in 6 hours, but total dose should not exceed 1.5 mg in 24 hours.</li>
                                        <li>Propress Vaginal Insert: Another vaginal insert formulation.</li>
                                        <li>Prostin E2 Vaginal Suppository: Vaginal suppositories containing 20 mg dinoprostone, used for cervical ripening and inducing abortion.</li>
                                    </ul>
                                </li>
                                <li>To induce abortion: To terminate pregnancy, typically in the second trimester, or to manage missed or incomplete abortion.
                                    <ul>
                                        <li>Prostin E2 Vaginal Suppository: One 20-mg vaginal suppository is inserted high into the vagina. Repeat doses may be administered every 3 to 5 hours until abortion occurs. Total dosage should not exceed 240 mg, and treatment duration should not exceed 48 hours.</li>
                                    </ul>
                                </li>
                            </ol>
                        </div>
                    </section>
                </div>
            </section>

            <section class="content-section">
                <h2>üìö Contraindications and Precautions of Dinoprostone</h2>
                <div class="content-block">
                    <section class="content-section">
                        <h3>Contraindications</h3>
                        <div class="content-block">
                            <ul>
                                <li>Hypersensitivity to prostaglandins or any component of dinoprostone preparations.</li>
                                <li>Ruptured membranes: Use is contraindicated in patients with ruptured amniotic membranes, as it increases the risk of infection.</li>
                                <li>Placenta previa or unexplained vaginal bleeding: Contraindicated in placenta previa (placenta blocking the cervix) or unexplained vaginal bleeding, due to risk of hemorrhage and complications.</li>
                                <li>Active labor: Not used if patient is already in active labor.</li>
                            </ul>
                        </div>
                    </section>
                    <section class="content-section">
                        <h3>Precautions</h3>
                        <div class="content-block">
                            <p>Use cautiously in patients with:</p>
                            <ul>
                                <li>Pulmonary, cardiac, renal, or hepatic disease: Monitor closely due to potential exacerbation of these conditions.</li>
                                <li>Asthma: May trigger bronchospasm in asthma patients.</li>
                                <li>Hypotension: Can cause or worsen hypotension.</li>
                                <li>Adrenal disorders: Use with caution in patients with adrenal suppression.</li>
                                <li>Diabetes mellitus: Monitor blood glucose levels, as prostaglandins can affect glucose control.</li>
                                <li>Epilepsy: May lower seizure threshold in patients with epilepsy.</li>
                                <li>Multiparity: Women with multiple previous pregnancies may be at increased risk of uterine rupture. Use with caution and monitor uterine activity closely.</li>
                            </ul>
                        </div>
                    </section>
                </div>
            </section>

            <section class="content-section">
                <h2>üìö Adverse reactions and Administration of Dinoprostone</h2>
                <div class="content-block">
                    <section class="content-section">
                        <h3>Adverse reactions</h3>
                        <div class="content-block">
                            <ul>
                                <li>Central Nervous System (CNS): Headache, drowsiness, syncope (fainting).</li>
                                <li>Cardiovascular (CV): Hypotension, hypertension, chest pain, atrial fibrillation, heart failure, palpitations.</li>
                                <li>Gastrointestinal (GI): Nausea, vomiting, diarrhea, abdominal pain.</li>
                                <li>Genitourinary (GU): Urinary tract infection, vaginal or uterine pain, uterine contractile abnormalities (hypertonicity, tetanic contractions, rupture). Warm vaginal sensation.</li>
                                <li>Musculoskeletal: Back pain.</li>
                                <li>Respiratory: Cough, dyspnea (shortness of breath), wheezing.</li>
                                <li>Other: Allergic reactions, including chills, fever, and anaphylaxis (rare but serious allergic reaction).</li>
                            </ul>
                        </div>
                    </section>
                    <section class="content-section">
                        <h3>Administration</h3>
                        <div class="content-block">
                            <ul>
                                <li>Patient Positioning: Keep patient supine (lying on back) for 15 to 30 minutes after gel administration and for at least 10 minutes after administering suppository to ensure drug absorption and prevent expulsion.</li>
                                <li>Storage: Store suppositories in a freezer to maintain stability; bring to room temperature before use to ease administration and insertion.</li>
                            </ul>
                        </div>
                    </section>
                </div>
            </section>

            <section class="practice-activity">
                <h2>‚úçÔ∏è Practice Exercise</h2>
                <div class="content-activity">
                    <p><strong>Question:</strong> Explain the mechanism of action of Dinoprostone in cervical ripening and labor induction. What are the key nursing assessments and monitoring parameters during Dinoprostone administration for labor induction?</p>
                    <details class="solution">
                        <summary>View Solution</summary>
                        <div class="solution-content">
                            <p><strong>Mechanism of Action of Dinoprostone in Cervical Ripening and Labor Induction:</strong> Dinoprostone, a synthetic prostaglandin E2 (PGE2) analog, facilitates cervical ripening and induces labor by mimicking the actions of endogenous prostaglandins at the end of pregnancy. Its mechanisms include:</p>
                            <ul>
                                <li>Cervical Ripening:
                                    <ul>
                                        <li>Collagen Breakdown: Dinoprostone acts on the cervix to promote cervical ripening, which involves breaking down the collagen structure of the cervix. This breakdown softens the cervix, making it more pliable and ready for dilation.</li>
                                        <li>Increased Water Content: Increases the water content and distensibility of the cervix.</li>
                                        <li>Cervical Effacement and Dilation: These changes lead to cervical effacement (thinning) and dilation (opening), preparing the cervix for labor and delivery.</li>
                                    </ul>
                                </li>
                                <li>Induction of Uterine Contractions:
                                    <ul>
                                        <li>Myometrial Stimulation: Dinoprostone stimulates contractions of the uterine smooth muscle (myometrium). It increases intracellular calcium concentrations in myometrial cells, which initiates and strengthens uterine contractions.</li>
                                        <li>Labor Induction: These contractions help to initiate and progress labor, leading to delivery of the fetus and placenta.</li>
                                    </ul>
                                </li>
                            </ul>
                            <p><strong>Key Nursing Assessments and Monitoring Parameters During Dinoprostone Administration for Labor Induction:</strong></p>
                            <ol>
                                <li>Uterine Contractions Monitoring: Continuous monitoring of uterine contractions is crucial to assess the response to dinoprostone and detect potential complications like uterine hyperstimulation.
                                    <ul>
                                        <li>Frequency, Duration, and Intensity: Monitor the frequency, duration, and intensity of uterine contractions using electronic fetal monitoring (EFM). Assess for tachysystole (excessively frequent contractions), which can compromise fetal oxygen supply.</li>
                                        <li>Uterine Resting Tone: Evaluate uterine resting tone between contractions to ensure the uterus relaxes adequately, preventing fetal distress.</li>
                                    </ul>
                                </li>
                                <li>Fetal Heart Rate (FHR) Monitoring: Continuous fetal heart rate monitoring is essential to assess fetal well-being and detect signs of fetal distress.
                                    <ul>
                                        <li>Baseline FHR, Variability, and Decelerations: Monitor baseline FHR, FHR variability, and presence of decelerations (especially late decelerations), which can indicate fetal stress or hypoxia due to uterine hyperstimulation or other complications.</li>
                                    </ul>
                                </li>
                                <li>Maternal Vital Signs: Monitor maternal vital signs regularly, including blood pressure, heart rate, and temperature.
                                    <ul>
                                        <li>Blood Pressure and Heart Rate: Assess for hypotension (a potential side effect) and tachycardia. Report significant changes promptly.</li>
                                        <li>Temperature: Monitor for fever, which could indicate infection, especially if membranes are ruptured.</li>
                                    </ul>
                                </li>
                                <li>Vaginal Bleeding and Cramping: Observe for excessive vaginal bleeding or increased cramping, which could indicate complications such as placental abruption or uterine hyperstimulation. Record sanitary pad count to quantify bleeding.</li>
                                <li>Assess for Adverse Reactions: Monitor for maternal side effects of dinoprostone, such as nausea, vomiting, diarrhea, fever, chills, and headache. Report significant adverse reactions.</li>
                                <li>Evaluate for GI Upset: Assess for gastrointestinal upset. To minimize nausea and vomiting, an antiemetic may be administered before dinoprostone therapy, as prescribed.</li>
                                <li>Patient Positioning: Ensure patient remains supine for 15 to 30 minutes after gel administration and at least 10 minutes after suppository insertion to promote drug absorption and prevent expulsion.</li>
                            </ol>
                        </div>
                    </details>
                </div>
            </section>
        </main>

        <footer class="module-footer">
            <section class="key-takeaways">
                <h2>üìö Key Takeaways</h2>
                <ul>
                    <li>Dinoprostone (PGE2 analog) ripens cervix and induces labor by stimulating uterine contractions and cervical changes.</li>
                    <li>Used for cervical ripening at term, labor induction, and abortion in the second trimester; administered via vaginal insert, gel, or suppository.</li>
                    <li>Contraindications include prostaglandin hypersensitivity, ruptured membranes, placenta previa; use cautiously in asthma, cardiac, renal, or hepatic diseases. Side effects: GI upset, headache, uterine hypertonicity.</li>
                    <li>Nursing care involves continuous monitoring of uterine contractions and fetal heart rate, assessing maternal vital signs, managing potential GI upset, and ensuring correct administration and patient positioning post-administration.</li>
                </ul>
            </section>

            <section class="knowledge-check">
                <h2>‚ö° Knowledge Check</h2>
                <div class="quiz-content">
                    <ol>
                        <li>Dinoprostone primarily acts to ripen the cervix by:
                            <br> a) Increasing estrogen levels <br> b) Breaking down cervical collagen <br> c) Reducing uterine contractions</li>
                        <li>A key nursing action during Dinoprostone administration for labor induction is to continuously monitor:
                            <br> a) Maternal temperature <br> b) Uterine contractions and fetal heart rate <br> c) Maternal blood glucose levels</li>
                        <li>A contraindication for Dinoprostone use is:
                            <br> a) Gestational hypertension <br> b) Ruptured membranes <br> c) Diabetes mellitus</li>
                    </ol>
                </div>
            </section>
        </footer>
    </article>
</body>
</html>